Samuel W Stull1, Jeremiah W Bertz, David H Epstein, Bethany C Bray, Stephanie T Lanza. 1. From the Department of Biobehavioral Health, The Pennsylvania State University, University Park, PA (SWS, STL); Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD (SWS, JWB, DHE); The University of Illinois at Chicago, Center for Dissemination and Implementation Science, Chicago, IL (BCB); The Edna Bennett Pierce Prevention Research Center, The Pennsylvania State University, University Park, PA (STL).
Abstract
OBJECTIVES: Anhedonia can accompany substance use disorders (SUDs); its severity may vary by substance type, severity of SUD symptoms, or psychiatric comorbidity. The goal of this study was to clarify the contribution of each. METHODS: Data were from participants aged 18 to 65 years in the National Epidemiologic Survey on Alcohol and Related Conditions III (n = 30,999; 51% women), a cross-sectional, nationally representative sample reporting lifetime DSM-5 symptoms and lifetime anhedonia. We used logistic regression to test how anhedonia was associated with specific SUDs and psychiatric disorders in respondents with one lifetime diagnosis. We used latent class analysis to assess the association of anhedonia with patterns of comorbidity in all respondents. RESULTS: Opioid use disorder (OUD) had the greatest odds of anhedonia relative to other SUDs (ORs [95% CIs]): mild alcohol use disorder (AUD) ( 3.33 [1.74, 6.38]), moderate/severe AUD ( 2.73 [1.41, 5.30]), and cannabis use disorder ( 3.21 [1.43, 7.19]), though not significantly greater than stimulant use disorder ( 2.44 [.88, 6.73]). Anhedonia was more likely in mood disorders and posttraumatic stress disorder (PTSD) than in any SUD, except for PTSD versus OUD (OR [95% CIs] = .98 [.47, 2.02]). In latent class analysis analyses, the poly disorder class, which included SUDs and other diagnoses, had greater odds of anhedonia than the Poly SUD (ORs [95% CIs] = 1.62 [1.25, 2.09] and AUD 2.89 [2.40, 3.48]) classes. CONCLUSIONS: People with OUD or a lifetime history of mood disorder or PTSD may be most likely to present to SUD treatment with anhedonia.
OBJECTIVES: Anhedonia can accompany substance use disorders (SUDs); its severity may vary by substance type, severity of SUD symptoms, or psychiatric comorbidity. The goal of this study was to clarify the contribution of each. METHODS: Data were from participants aged 18 to 65 years in the National Epidemiologic Survey on Alcohol and Related Conditions III (n = 30,999; 51% women), a cross-sectional, nationally representative sample reporting lifetime DSM-5 symptoms and lifetime anhedonia. We used logistic regression to test how anhedonia was associated with specific SUDs and psychiatric disorders in respondents with one lifetime diagnosis. We used latent class analysis to assess the association of anhedonia with patterns of comorbidity in all respondents. RESULTS: Opioid use disorder (OUD) had the greatest odds of anhedonia relative to other SUDs (ORs [95% CIs]): mild alcohol use disorder (AUD) ( 3.33 [1.74, 6.38]), moderate/severe AUD ( 2.73 [1.41, 5.30]), and cannabis use disorder ( 3.21 [1.43, 7.19]), though not significantly greater than stimulant use disorder ( 2.44 [.88, 6.73]). Anhedonia was more likely in mood disorders and posttraumatic stress disorder (PTSD) than in any SUD, except for PTSD versus OUD (OR [95% CIs] = .98 [.47, 2.02]). In latent class analysis analyses, the poly disorder class, which included SUDs and other diagnoses, had greater odds of anhedonia than the Poly SUD (ORs [95% CIs] = 1.62 [1.25, 2.09] and AUD 2.89 [2.40, 3.48]) classes. CONCLUSIONS: People with OUD or a lifetime history of mood disorder or PTSD may be most likely to present to SUD treatment with anhedonia.
Authors: Thomas Insel; Bruce Cuthbert; Marjorie Garvey; Robert Heinssen; Daniel S Pine; Kevin Quinn; Charles Sanislow; Philip Wang Journal: Am J Psychiatry Date: 2010-07 Impact factor: 18.112
Authors: Margaret C Wardle; Jessica N Vincent; Robert Suchting; Charles E Green; Scott D Lane; Joy M Schmitz Journal: J Subst Abuse Treat Date: 2016-09-09
Authors: Bridget F Grant; Tulshi D Saha; W June Ruan; Risë B Goldstein; S Patricia Chou; Jeesun Jung; Haitao Zhang; Sharon M Smith; Roger P Pickering; Boji Huang; Deborah S Hasin Journal: JAMA Psychiatry Date: 2016-01 Impact factor: 21.596